Are Analysts Bullish about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) after last week?

August 9, 2018 - By Robert Shackelford

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) LogoInvestors sentiment decreased to 1.15 in 2018 Q1. Its down 0.16, from 1.31 in 2017Q4. It turned negative, as 24 investors sold Intercept Pharmaceuticals, Inc. shares while 35 reduced holdings. 20 funds opened positions while 48 raised stakes. 18.85 million shares or 4.89% more from 17.97 million shares in 2017Q4 were reported.
Rothschild Invest Corporation Il holds 0.04% or 5,164 shares in its portfolio. Tower Research Capital Ltd Liability (Trc) stated it has 0.01% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Jane Street Gp Lc holds 22,429 shares or 0% of its portfolio. Royal Commercial Bank Of Canada owns 92,467 shares for 0% of their portfolio. Peak6 Invs L P holds 0% or 1,462 shares. Credit Agricole S A stated it has 17,000 shares or 0.07% of all its holdings. Qvt Fincl L P has 11,254 shares for 0.07% of their portfolio. Hudock Grp Limited Liability Com stated it has 50 shares. Daiwa Secs Grp owns 139 shares for 0% of their portfolio. California-based Cap has invested 0.02% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Earnest Prns Ltd Liability Corporation stated it has 2 shares. C Ww Gru A S, a Denmark-based fund reported 1,244 shares. Altrinsic Global Advsr Limited Liability Company holds 0.93% or 375,223 shares. The Connecticut-based Ellington Gru Limited Liability Corp has invested 0.02% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Eulav Asset reported 80,000 shares or 0.24% of all its holdings.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 6 analysts covering Intercept Pharma (NASDAQ:ICPT), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Intercept Pharma had 8 analyst reports since February 12, 2018 according to SRatingsIntel. BMO Capital Markets maintained the shares of ICPT in report on Thursday, February 15 with “Outperform” rating. The rating was upgraded by Goldman Sachs to “Buy” on Monday, August 6. Wedbush maintained the stock with “Buy” rating in Monday, February 12 report. The company was downgraded on Friday, August 3 by Laidlaw. Wedbush maintained it with “Outperform” rating and $217 target in Monday, August 6 report. On Tuesday, April 17 the stock rating was maintained by Wedbush with “Outperform”. The firm earned “Hold” rating on Tuesday, February 13 by Wells Fargo. Below is a list of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) latest ratings and price target changes.

06/08/2018 Broker: Goldman Sachs Old Rating: Sell New Rating: Buy New Target: $157 Upgrade
06/08/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $203 New Target: $217 Maintain
03/08/2018 Broker: Laidlaw Old Rating: Buy New Rating: Hold Old Target: $90 New Target: $95 Downgrade
28/06/2018 Broker: Raymond James Rating: Strong Buy New Target: $122 Initiates Coverage On
17/04/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $256 New Target: $203 Maintain
15/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $152 New Target: $155 Maintain
13/02/2018 Broker: Wells Fargo Rating: Hold New Target: $57.0 Maintain
12/02/2018 Broker: Wedbush Rating: Buy New Target: $253.0 Maintain

The stock decreased 0.08% or $0.09 during the last trading session, reaching $116.75. About 102,752 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has declined 38.34% since August 9, 2017 and is downtrending. It has underperformed by 50.91% the S&P500.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $3.45 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Nasdaq.com which released: “Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community …” on July 25, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on August 06, 2018, Benzinga.com published: “52 Biggest Movers From Yesterday” on August 07, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Seekingalpha.com and their article: “Rounds Report: Intercept Is Gaining Momentum After Upbeat Earnings” published on August 03, 2018 as well as Benzinga.com‘s news article titled: “44 Stocks Moving In Monday’s Mid-Day Session” with publication date: August 06, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.